Form 4: Vivani Medical Director Receives Stock Options

Vivani Medical, Inc. reports an annual stock option grant to Director Daniel Bradbury.

Summary

• Director Daniel Bradbury received an annual grant of 36,516 non-qualified stock options.
• The options have an exercise price of $1.22 per share.
• The grant was made on June 24, 2026.
• These options vest on the earlier of the first anniversary of the grant or the next annual stockholder meeting, provided service continues.
• The options have an expiration date of June 23, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine director compensation event rather than a significant financial or strategic development.

Positives

• Director compensation aligns with the company's Non-Employee Director Compensation Policy.
• The stock options provide a potential incentive for the director to contribute to the company's long-term success.
• The vesting schedule encourages continued service.

Negatives

• The filing does not contain any negative information.

Risks

• The value of the stock options is subject to market fluctuations and the company's future performance.
• If the company's stock price does not exceed the exercise price of $1.22, the options may not be exercised profitably.

Future Outlook

The future outlook is tied to the vesting and potential exercise of the stock options, which are dependent on continued service and the company's stock performance.

Industry Context

StockSavvy.ai notes that grants of stock options to directors are a common practice in the biotechnology and medical technology sectors as a means to attract, retain, and incentivize key leadership, aligning their interests with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice across the biotechnology industry, similar to companies like Moderna (MRNA) and BioNTech (BNTX) which also utilize equity-based compensation to align executive and director interests with long-term shareholder value.
• The exercise price of $1.22 is within a typical range for early-stage or growth-oriented companies in the sector, reflecting the inherent risks and potential rewards associated with their development pipelines.

Stakeholder Impact

• Shareholders: The grant of options dilutes existing share ownership slightly, but also aligns director incentives with long-term shareholder value creation.
• Employees: This filing does not directly impact employees.
• Creditors: This filing has no direct impact on creditors.
• Suppliers: This filing has no direct impact on suppliers.
• Customers: This filing has no direct impact on customers.

Next Steps

• Director Daniel Bradbury will continue to provide service to Vivani Medical, Inc.
• The stock options will vest according to the schedule outlined.
• The options may be exercised by the director if the stock price exceeds the exercise price before the expiration date.

Key Dates

Keywords

Vivani Medical, VANI, Form 4, Stock Options, Director Compensation, SEC Filing, Beneficial Ownership, Grant